Kura Oncology Financials

$382.1 M

Mkt cap, 20-Apr-2018
Net income (FY, 2017)(35.4 M)
Cash, 31-Dec-201711.4 M
EV377.8 M

Revenue/Financials

Income Statement

Annual

USDFY, 2016FY, 2017

R&D expense

25.1 m

General and administrative expense

9.4 m

Operating expense total

36.1 m

Interest expense

888 k

Interest income

751 k

Net Income

(27.6 m)(35.4 m)

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

R&D expense

3.3 m3 k3.6 m4 m4.3 m5.2 m5.2 m

General and administrative expense

1.5 m63 k2.4 m1.8 m1.7 m2.1 m2.2 m

Operating expense total

5.9 m66 k7 m6.8 m7.1 m7.7 m7.9 m9.5 m

Interest expense

42 k42 k42 k189 k194 k203 k209 k226 k

Interest income

22 k38 k114 k124 k131 k128 k124 k197 k

Net Income

(5.6 m)(66 k)(6.6 m)(6.7 m)(6.9 m)(7.5 m)(7.8 m)(9.3 m)

Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

6.6 k5.6 k15.4 m9.7 m11.4 m

Accounts Receivable

92.4 m

Inventories

693 k725 k

Current Assets

86.9 m68.8 m94.6 m

PP&E

71 k40 k10 k

Total Assets

9.1 k5.6 k87.3 m69.8 m95.9 m

Accounts Payable

350 2.4 k4.1 m4.7 m8.3 m

Short-term debt

1.5 m

Current Liabilities

5.1 m5.5 m10 m

Long-term debt

5.6 m

Total Debt

7.1 m

Total Liabilities

12.9 m16 m

Additional Paid-in Capital

49.5 k49.5 k108.5 m110.7 m169.2 m

Retained Earnings

(26.3 m)(53.9 m)(89.3 m)

Total Equity

(124 k)(154.7 k)82.1 m56.9 m79.9 m

Financial Leverage

-0.1 x0 x1.1 x1.2 x1.2 x

Quarterly

USDQ3, 2017

Inventories

909 k

Accounts Payable

6.2 m

Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(28.6 k)(30.7 k)(3.7 m)(27.6 m)(35.4 m)

Depreciation and Amortization

1 k31 k30 k

Accounts Receivable

Inventories

(42 k)(32 k)

Accounts Payable

(1.5 k)2.1 k833 k471 k3.6 m

Cash From Operating Activities

(23.2 k)(16 k)(849 k)(25.3 m)(28.4 m)

Purchases of PP&E

(28 k)(64 k)

Cash From Investing Activities

(28 k)12.2 m(23.4 m)

Cash From Financing Activities

25 k15 k2 m7.5 m53.6 m

Interest Paid

352 k627 k

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(5.6 m)(66 k)(6.6 m)(6.7 m)(6.9 m)(7.5 m)(9.3 m)

Inventories

909 k

Accounts Payable

650 713 8.2 k10.7 k2.5 m3.7 m3.1 m3.3 m4.2 m3.7 m4.2 m6.2 m

Ratios

USDY, 2017

EV/CFO

-13.3 x

Financial Leverage

1.2 x
Report incorrect company information

Operating Metrics

FY, 2016

Phase II Trials Products

1

Preclinical Phase Products

2
Report incorrect company information